ADC	Antibody–drug conjugate
AE(s)	Adverse event(s)
bAbs	Bispecific antibodies
BC	Breast cancer
ECD	Extracellular domain
EGFR	Epidermal growth factor receptor
ER +	Estrogen receptor positive
ESCC	Esophageal squamous cell carcinoma
HER2 +	HER2-amplified
HNSCC	Head and neck squamous cell carcinoma
HRG	Heregulin
IGF1R	Insulin-like growth factor 1 receptor
IMA	Invasive mucinous adenocarcinomas
MoAbs	Monoclonals antibodies
NRG(s)	Neuregulin(s)
NSCLC	Non-small cell lung cancers
OS	Overall survival
PD-1	Programmed cell death-1
PFS	Progression-free survival
PR	Partial response
RAI	Radioactive iodine
RP2D	Recommended phase 2 dose
RTK	Receptor tyrosine kinases
scDb	Bispecific single-chain diabody
T-DM1	Trastuzumab-emtansine
TKIs	Tyrosine kinase inhibitors
TNBC	Triple-negative breast cancer